NO904120L - Protein-inneholdende vandige loesninger. - Google Patents

Protein-inneholdende vandige loesninger.

Info

Publication number
NO904120L
NO904120L NO90904120A NO904120A NO904120L NO 904120 L NO904120 L NO 904120L NO 90904120 A NO90904120 A NO 90904120A NO 904120 A NO904120 A NO 904120A NO 904120 L NO904120 L NO 904120L
Authority
NO
Norway
Prior art keywords
protein
aqueous solutions
containing aqueous
dissolved
salt
Prior art date
Application number
NO90904120A
Other languages
English (en)
Norwegian (no)
Other versions
NO904120D0 (no
Inventor
Yukio Shimazaki
Nobuhiro Kawashima
Miki Yoshioka
Yasuhito Tanaka
Ryo Tanaka
Kiyoshi Sakai
Hisahiro Ishiwari
Original Assignee
Mitsui Toatsu Chemicals
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsui Toatsu Chemicals, Mochida Pharm Co Ltd filed Critical Mitsui Toatsu Chemicals
Publication of NO904120D0 publication Critical patent/NO904120D0/no
Publication of NO904120L publication Critical patent/NO904120L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO90904120A 1989-09-21 1990-09-20 Protein-inneholdende vandige loesninger. NO904120L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1243311A JPH0791318B2 (ja) 1989-09-21 1989-09-21 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤

Publications (2)

Publication Number Publication Date
NO904120D0 NO904120D0 (no) 1990-09-20
NO904120L true NO904120L (no) 1991-03-22

Family

ID=17101947

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90904120A NO904120L (no) 1989-09-21 1990-09-20 Protein-inneholdende vandige loesninger.

Country Status (14)

Country Link
EP (1) EP0419251B1 (de)
JP (1) JPH0791318B2 (de)
KR (1) KR930004598B1 (de)
CN (1) CN1049356C (de)
AT (1) ATE93731T1 (de)
AU (1) AU627621B2 (de)
BR (1) BR9004693A (de)
CA (1) CA2025315C (de)
DE (1) DE69003061T2 (de)
DK (1) DK0419251T3 (de)
ES (1) ES2060057T3 (de)
FI (1) FI98891C (de)
NO (1) NO904120L (de)
NZ (1) NZ235297A (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1602667B1 (de) * 1995-06-07 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Waessrige Formulierung enthaltend TFPI und Lösungsvermittlers
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107185A (en) * 1981-10-07 1983-04-27 John Kenneth Mcmullen Insulin formulations containing surface-active agents
EP0156169B1 (de) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha Wässrige Lösung eines darin in erhöhter Konzentration aufgelösten Gewebe-Plasminogen-Aktivators und Herstellungsverfahren
DE3512908A1 (de) * 1985-04-11 1986-10-23 Behringwerke Ag, 3550 Marburg Gewebe-plasminogenaktivator (t-pa) enthaltendes mittel
JPS61289886A (ja) * 1985-06-19 1986-12-19 Agency Of Ind Science & Technol 酵素及び／又は微生物含有アルギン酸繊維紙の製造法
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4857320A (en) * 1987-02-19 1989-08-15 Monsanto Company Method of enhancing the solubility of tissue plasminogen activator
JPH02111726A (ja) * 1988-10-19 1990-04-24 Dainippon Pharmaceut Co Ltd ヒト　インターロイキン１を安定化する方法

Also Published As

Publication number Publication date
EP0419251A1 (de) 1991-03-27
FI904618A0 (fi) 1990-09-19
CN1049356C (zh) 2000-02-16
NZ235297A (en) 1992-12-23
FI98891C (fi) 1997-09-10
KR910005884A (ko) 1991-04-27
NO904120D0 (no) 1990-09-20
DE69003061T2 (de) 1993-12-16
DK0419251T3 (da) 1994-01-31
JPH0791318B2 (ja) 1995-10-04
FI98891B (fi) 1997-05-30
JPH03106898A (ja) 1991-05-07
CA2025315A1 (en) 1991-03-22
ES2060057T3 (es) 1994-11-16
EP0419251B1 (de) 1993-09-01
KR930004598B1 (ko) 1993-06-01
CN1050327A (zh) 1991-04-03
BR9004693A (pt) 1991-09-10
CA2025315C (en) 1997-01-07
AU627621B2 (en) 1992-08-27
DE69003061D1 (de) 1993-10-07
AU6246690A (en) 1991-03-28
ATE93731T1 (de) 1993-09-15

Similar Documents

Publication Publication Date Title
ATE74519T1 (de) Waessrige loesung von fettloeslichen wirkstoffen.
NO875299D0 (no) Insulinpreparat for ikke-paranteral administrasjon.
FI870169A0 (fi) Stabiliserat tokoferol i fri-flytande partikelform.
BG46601A3 (bg) Метод за получаване на авермектинови производни
ES2029853T5 (es) Base de unguento y unguento.
DE3852140D1 (de) Produktion von Proteinen in aktiven Formen.
DK0454898T3 (da) Glycosaminoglycan-modificeret protein, fremgangsmåde til fremstilling af proteinet, farmaceutiske præparater indeholdende proteinet samt anvendelse af proteinet
SE8602405D0 (sv) Ny formulering
SE8505048L (sv) Nutritionsemulsion med syretransporterande egenskaper
ATE125706T1 (de) Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis.
SE7904118L (sv) Sett att framstella en urokinaskomposition
DK0490549T3 (da) Stabilisering af calcitonin-holdige farmaceutiske præparater
FI882605A0 (fi) Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta
NO904120L (no) Protein-inneholdende vandige loesninger.
DK0431465T3 (da) Vandig dialyse- og skylleopløsning
EP0981571A4 (de) Reinigung von polyphosphazensäure
DE68902223D1 (de) Waesserige loesungen von doxorubicin.
EP0214281A4 (de) Mittel zur absorptionsverbesserung von proteinen.
ATE23161T1 (de) 3-deazaguanin-sulfonsaeuresalze.